Head-to-head evidence
AZD8233 vs Evolocumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
AZD8233
Developed by AstraZeneca
NCT03593785 · Phase 1 · completed
This is a randomized, placebo-controlled, single ascending-dose study, though blinding is limited to participants rather than the full study team. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Evolocumab · Repatha
Marketed by Amgen
NCT01516879 · Phase 3 · completed
The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome.
Next expected readout: November 2026 · NCT06496243 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD8233's landscape · Evolocumab's landscape